All > Lou Gehrigs Disease > Als

QRL-201 - Arm 1 for ALS (Amyotrophic Lateral Sclerosis)

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
ALS (Amyotrophic Lateral Sclerosis)QRL-201 - Dose 7 - Drug
Eligibility
18 - 80
All Sexes
What conditions do you have?
Select

Study Summary

The primary objective of this study is to determine the safety and tolerability of multiple doses of QRL-201 in people living with ALS

Eligible Conditions
  • ALS (Amyotrophic Lateral Sclerosis)

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

1
Ribociclib
1
Olaparib
1
Fulvestrant

Study Objectives

1 Primary · 3 Secondary · Reporting Duration: Baseline through 253 Days

Baseline through 253 Days
Number of participants with one or more treatment emergent adverse events and serious adverse events
Hour 24
Pharmacokinetics (plasma): Area under the concentration time curve from zero to infinity (AUCinf) of QRL-201
Pharmacokinetics (plasma): Maximum observed concentration of QRL-201 (Cmax)
Pharmacokinetics (plasma): Time of maximum concentration (Tmax) of QRL-201

Trial Safety

Safety Progress

1 of 3

Similar Trials

1
Ribociclib
2
Olaparib
2
Fulvestrant

Trial Design

8 Treatment Groups

QRL-201 - Arm 1
1 of 8
QRL-201 - Arm 8
1 of 8
QRL-201 - Arm 3
1 of 8
QRL-201 - Arm 2
1 of 8
QRL-201 - Arm 4
1 of 8
QRL-201 - Arm 7
1 of 8
QRL-201 - Arm 5
1 of 8
QRL-201 - Arm 6
1 of 8

Experimental Treatment

64 Total Participants · 8 Treatment Groups

Primary Treatment: QRL-201 - Arm 1 · No Placebo Group · Phase 1

QRL-201 - Arm 1
Drug
Experimental Group · 1 Intervention: QRL-201 - Dose 1 · Intervention Types: Drug
QRL-201 - Arm 8
Drug
Experimental Group · 1 Intervention: QRL-201- Dose 8 · Intervention Types: Drug
QRL-201 - Arm 3
Drug
Experimental Group · 1 Intervention: QRL-201 - Dose 3 · Intervention Types: Drug
QRL-201 - Arm 2
Drug
Experimental Group · 1 Intervention: QRL-201 - Dose 2 · Intervention Types: Drug
QRL-201 - Arm 4
Drug
Experimental Group · 1 Intervention: QRL-201 - Dose 4 · Intervention Types: Drug
QRL-201 - Arm 7
Drug
Experimental Group · 1 Intervention: QRL-201 - Dose 7 · Intervention Types: Drug
QRL-201 - Arm 5
Drug
Experimental Group · 1 Intervention: QRL-201 - Dose 5 · Intervention Types: Drug
QRL-201 - Arm 6
Drug
Experimental Group · 1 Intervention: QRL-201 - Dose 6 · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: baseline through 253 days

Who is running the clinical trial?

QurAlis CorporationLead Sponsor
1 Previous Clinical Trials
40 Total Patients Enrolled
Angela Genge, MDStudy DirectorQurAlis Corporation

Eligibility Criteria

Age 18 - 80 · All Participants · 7 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have a male or female participant aged 18 to 80 years diagnosed with ALS.
You have slow vital capacity.
You are not pregnant or nursing.\n
You are able to tolerate a lumbar puncture.
You must be on a stable dose of the ALS drug.
References

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top